Author | Lisa Astor


FDA Denies Approval of Pembrolizumab/Lenvatinib for Frontline Unresectable HCC

July 08, 2020


The FDA has issued a complete response letter in regard to the applications for potential accelerated approval of pembrolizumab in combination with lenvatinib as treatment of patients with previously untreated, unresectable hepatocellular carcinoma.

Frontline NALIRIFOX Regimen Demonstrates Promising Activity in Advanced PDAC

July 02, 2020


Long-term follow-up results from the study were presented in a poster at the virtual 2020 European Society of Medical Oncology World Congress on Gastrointestinal Cancer meeting.

FDA Approves Frontline Pembrolizumab for MSI-H/dMMR CRC

June 29, 2020


"Patients with unresectable or metastatic MSI-H colorectal cancer have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options."